Business Context and Reporting Period
Mobia Medical, Inc. (formerly MicroTransponder, Inc.) is a commercial-stage medical device company focused on the Vivistim Paired Vagus Nerve Stimulation (Paired VNS) System, an FDA-approved treatment for chronic ischemic stroke survivors. The company completed its Initial Public Offering (IPO) in May 2026, raising approximately $134.0 million in net proceeds. This report covers the quarterly period ended June 30, 2026.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $13.5 million | $25.6 million |
| Gross Profit | $11.2 million | $21.2 million |
| Gross Margin | 83.2% | 82.8% |
| Net Loss | $(21.0) million | $(38.8) million |
| Cash and Cash Equivalents | $177.1 million (as of June 30, 2026) | |
| Accumulated Deficit | $(196.6) million (as of June 30, 2026) | |
| Debt Outstanding | $7.3 million (Notes Payable, net of discount) |
Liquidity: The company generated a net cash outflow from operating activities of $33.4 million for the six months ended June 30, 2026. Financing activities provided $178.5 million, primarily driven by the IPO and convertible note issuances.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 102.4% year-over-year for the quarter and 107.4% for the six-month period, driven by higher adoption of the Vivistim System and increased unit sales.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses surged 85.0% for the quarter and 85.1% for the six-month period. This increase is attributed to expanded commercial headcount, higher commissions, and costs associated with the IPO and name change.
- Non-Operating Items: The company recognized a $4.1 million loss (quarter) and $4.9 million loss (six months) due to the change in fair value of convertible notes payable, which were converted to common stock upon the IPO completion.
- Capital Structure: All outstanding redeemable convertible preferred stock and convertible promissory notes were converted to common stock immediately prior to the IPO in May 2026.
Outlook, Risks, and Management Commentary
- Going Concern: Management concluded that the IPO proceeds provide sufficient liquidity to fund operations for at least 12 months, removing the substantial doubt about the company's ability to continue as a going concern that existed in prior periods.
- Commercial Strategy: The company is aggressively scaling its commercial organization to drive awareness and adoption at primary and comprehensive stroke centers. SG&A expenses are expected to continue increasing as the team expands.
- Reimbursement: Effective January 1, 2026, the Vivistim System implantation procedure was assigned a New Technology Ambulatory Payment Classification (APC) by CMS, establishing an elevated payment level.
- Material Weakness: The company identified a material weakness in internal controls over financial reporting related to the calculation of net loss per share. Remediation controls were implemented in Q1 2026, but the weakness is not yet considered fully remediated.
- Risks: Key risks include dependence on third-party manufacturers (including single-source suppliers in Uruguay), the need for continued reimbursement coverage, and the ability to secure additional financing if revenue growth does not meet expectations.
Investor Verification Checklist
- Verify the sustainability of the 83% gross margin as sales volume scales and potential tariff impacts are realized.
- Monitor the burn rate and cash runway given the significant increase in SG&A expenses relative to revenue.
- Confirm the status of the remediation plan for the material weakness in internal controls over financial reporting.
- Assess the impact of the new CMS APC payment classification on actual reimbursement rates and prior authorization success.
- Review the concentration risk regarding third-party contract manufacturers in Uruguay and potential supply chain disruptions.